The interventions toward disease are moving forward to early screening and early diagnosis.
GeneBioHealth (Chinese: 晋百慧生物) has recently completed the Series B+ financing round led by strategic investors BOC&UTRUST Private Equity Fund Management (Chinese: 中银粤财基金) worth USD 15 million.
The fund will be mainly used to research and develop multiple pipeline products.
Colorectal cancer is one of the most common malignant tumors. According to the Cancer statistics in China 2022, the incidence rate and mortality rate of colorectal cancer in China rank fourth and fifth among all malignant tumors. Most patients were already in the middle or late stages of their diagnosis.
The precancerous development process of colorectal cancer can vary from three to several years, providing time for early screening and clinical intervention. And a large number of early screening enterprises have emerged.
GeneBioHealth and Professor Yu Jun's research team from the Chinese University of Hong Kong have developed REColonTMmiR-92a Assay Kit. The team comprehensively analyzed multiple strategies such as detecting gene methylation, mRNA and microRNA from blood and stool samples and selected miRNA-92a (the first identified targeting of microRNA in the tumor) as candidates due to its stable existence in vitro, good detection repeatability, high detection sensitivity and a high degree of specificity in colon cancer.
At present, the enterprises that NMPA has approved for the early detection kit of colorectal cancer include AmoyDx (Chinese: 艾德生物), Ammunition Life Technology (Chinese: 艾米森生物科技) and New Horizon Health (Chinese: 诺辉健康), etc.